View Older Stories View More Recent Stories

Jun 12, 2017 10:00AM Bristol-Myers Squibb to Announce Results for Second Quarter 2017 on July 27
Jun 8, 2017 07:33AM Bristol-Myers Squibb's (BMY) New ORENCIA (abatacept) Subcutaneous for Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis Now Available
Jun 8, 2017 07:30AM Bristol-Myers Squibb Announces Availability of New ORENCIA® (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juven
Jun 7, 2017 06:59AM Bristol-Myers Squibb to Take Part in Goldman Sachs 38th Annual Global Healthcare Conference
Jun 5, 2017 04:08PM Bristol-Myers Squibb (BMY) New Collaboration WIth Novartis (NVS) To Evaluate Combo Therapy In Colorectal Cancer
Jun 5, 2017 04:05PM Bristol-Myers Squibb Announces New Collaboration to Evaluate Combination Therapy in Colorectal Cancer
Jun 5, 2017 07:35AM Incyte (INCY), Bristol-Myers Squibb (BMY) Announce Trial Data for Combination of Epacadostat and Opdivo Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer
Jun 5, 2017 07:33AM Bristol-Myers Squibb (BMY) Announces Positive Results from IFCT-1501 MAPS-2 Trial
Jun 5, 2017 07:30AM Encouraging Disease Control Rates Observed with Nivolumab Alone or in Combination with Ipilimumab in Refractory or Relapsing Malignant Pleural Mesothelioma Patients: Results from IFCT-1501 MAPS-2 Tria
Jun 5, 2017 07:30AM Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer
Jun 5, 2017 07:22AM Bristol-Myers Squibb (BMY) Says Early, Durable Responses Seen with Sprycel in First- and Second-Line Treatment of Pediatric Patients with CP-CML
Jun 5, 2017 07:15AM Early, Durable Responses Seen with Sprycel (dasatinib) in First- and Second-Line Treatment of Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
Jun 5, 2017 06:23AM Bristol-Myers Squibb (BMY) Announces New Data Evaluating the Safety & Preliminary Relapse-Free Survival of Adjuvant Yervoy at ASCO Meetings
Jun 5, 2017 06:17AM Bristol-Myers Squibb (BMY) Presents Efficacy Data from CheckMate -204 Evaluating the Combination of Opdivo (nivolumab) & Yervoy (ipilimumab) at ASCO Meetings
Jun 5, 2017 05:58AM Bristol-Myers Squibb (BMY) & Qiagen (QGEN) Announce Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies
Jun 5, 2017 05:51AM Bristol-Myers Squibb (BMY) Announces Data on Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) at ASCO Meetings
Jun 5, 2017 05:45AM Bristol-Myers Squibb (BMY) Announces Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therap
Jun 4, 2017 08:30AM New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients Presented at ASCO
Jun 4, 2017 08:00AM First Presentation of Efficacy Data from CheckMate -204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with B
Jun 3, 2017 01:00PM Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies
Jun 3, 2017 09:00AM Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrated Promising Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer in Phase 2 CheckMate -142 Stud
Jun 3, 2017 08:00AM Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy
Jun 2, 2017 05:06PM Bristol-Myers Squibb (BMY) Granted European Commission Approval Opdivo (Nivolumab)
Jun 2, 2017 05:00PM European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platin
Jun 2, 2017 07:00AM Bristol-Myers Squibb (BMY) Says Opdivo Data from Phase 1/2 CheckMate -358 Presented at ASCO
Jun 2, 2017 06:59AM Opdivo (nivolumab) Data in Patients with Advanced Cervical, Vaginal and Vulvar Cancers from Phase 1/2 CheckMate -358 Presented at ASCO
Jun 2, 2017 06:03AM Bristol-Myers Squibb (BMY) & Seattle Genetics (SGEN) Announce Expanded Collaboration to Evaluate Combination of Opdivo (Nivolumab) & ADCETRIS (Brentuximab Vedotin) in Phase 3 Clinical Trial
Jun 2, 2017 06:00AM Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and ADCETRIS® (Brentuximab Vedotin) in Pivotal Phase 3 Clinical Trial in Relapsed
May 30, 2017 07:01AM Bristol-Myers Squibb (BMY) & Advaxis (ADXS) Report Clinical Collaboration to Evaluate ADXS-DUAL & Opdivo (Nivolumab) in Metastatic Cervical Cancer
May 30, 2017 06:59AM Array Biopharma (ARRY), Bristol-Myers Squibb (BMY) Enter Strategic Collaboration
May 30, 2017 06:59AM Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer
May 30, 2017 06:59AM Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
May 30, 2017 06:59AM Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
May 26, 2017 06:59AM Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
May 26, 2017 06:59AM CORRECTING and REPLACING Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
May 24, 2017 11:16AM Bristol-Myers Squibb (BMY) Announces FDA Accepts Opdivo sBLA for Priority Review for Treatment of HCC
May 24, 2017 11:15AM U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma
May 19, 2017 08:13AM European Medicines Agency Validates Application for Bristol-Myers Squibb’s Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia
May 17, 2017 05:00PM Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017
May 16, 2017 06:59AM Bristol-Myers Squibb to Take Part in UBS Global Healthcare Conference
May 10, 2017 07:01AM Bristol-Myers (BMY), Calithera Biosciences (CALA) Expand Collaboration Evaluating Opdivo in Combination with CB-839 for NSCLC
May 10, 2017 06:59AM Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma
May 10, 2017 06:59AM Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma
Apr 28, 2017 02:39PM Bristol-Myers Squibb (BMY) Announce EC Approval for Opdivo for Squamous Cell Cancer of Head and Neck
Apr 28, 2017 02:38PM European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy
Apr 28, 2017 07:19AM China FDA Approves Country’s First All-Oral Regimen for Chronic Hepatitis C, Daklinza® (daclatasvir) in Combination with Sunvepra® (asunaprevir)
Apr 27, 2017 08:00AM Bristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference
Apr 27, 2017 06:59AM Bristol-Myers Squibb Reports First Quarter Financial Results
Apr 25, 2017 01:30AM Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
Apr 25, 2017 01:30AM Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
View More Recent Stories View Older Stories